JP4847634B2 - 中枢神経系の虚血または外傷の機能的回復を増大させる方法 - Google Patents

中枢神経系の虚血または外傷の機能的回復を増大させる方法 Download PDF

Info

Publication number
JP4847634B2
JP4847634B2 JP53358397A JP53358397A JP4847634B2 JP 4847634 B2 JP4847634 B2 JP 4847634B2 JP 53358397 A JP53358397 A JP 53358397A JP 53358397 A JP53358397 A JP 53358397A JP 4847634 B2 JP4847634 B2 JP 4847634B2
Authority
JP
Japan
Prior art keywords
residue
xaa
morphogen
pharmaceutical composition
bmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP53358397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000506894A (ja
Inventor
チャレット，マーク，エフ．
フィンクルステイン，セス，ピー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stryker Corp
Original Assignee
Stryker Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24485972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4847634(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Stryker Corp filed Critical Stryker Corp
Publication of JP2000506894A publication Critical patent/JP2000506894A/ja
Application granted granted Critical
Publication of JP4847634B2 publication Critical patent/JP4847634B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of Electric Motors In General (AREA)
  • Protection Of Generators And Motors (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP53358397A 1996-03-22 1997-03-21 中枢神経系の虚血または外傷の機能的回復を増大させる方法 Expired - Fee Related JP4847634B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62044496A 1996-03-22 1996-03-22
US08/620,444 1996-03-22
PCT/US1997/004177 WO1997034626A1 (en) 1996-03-22 1997-03-21 Methods for enhancing functional recovery following central nervous system ischemia or trauma

Publications (2)

Publication Number Publication Date
JP2000506894A JP2000506894A (ja) 2000-06-06
JP4847634B2 true JP4847634B2 (ja) 2011-12-28

Family

ID=24485972

Family Applications (2)

Application Number Title Priority Date Filing Date
JP53358397A Expired - Fee Related JP4847634B2 (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷の機能的回復を増大させる方法
JP9533791A Withdrawn JP2000507939A (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP9533791A Withdrawn JP2000507939A (ja) 1996-03-22 1997-03-21 中枢神経系の虚血または外傷後のポリペプチド成長因子の投与

Country Status (11)

Country Link
US (4) US6407060B1 (index.php)
EP (3) EP0894004B2 (index.php)
JP (2) JP4847634B2 (index.php)
KR (1) KR20000064752A (index.php)
CN (1) CN1181885C (index.php)
AT (2) ATE493141T1 (index.php)
AU (2) AU734312B2 (index.php)
CA (2) CA2249596C (index.php)
DE (2) DE69723429T3 (index.php)
ES (1) ES2201287T5 (index.php)
WO (2) WO1997034626A1 (index.php)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
EP1770161A3 (en) 1993-05-12 2008-04-23 Genetics Institute, LLC BMP-11 compositions
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
ATE319823T1 (de) 1993-12-07 2006-03-15 Inst Genetics Llc Bmp-12, bmp-13 und diese enthaltende sehne- induzierende zusammensetzungen
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues
JP5033276B2 (ja) 1997-05-05 2012-09-26 ストライカー コーポレイション 急性腎不全の治療
EP0985149A1 (en) * 1997-05-30 2000-03-15 Creative Biomolecules, Inc. Methods for evaluating tissue morphogenesis and activity
AU1706499A (en) * 1997-12-04 1999-06-16 Curis, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
DE19837230A1 (de) * 1998-08-17 2000-03-09 Jean Krutmann Neurotrophin-4 zur Behandlung von Tumoren neuroektodermalen Ursprungs
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
US6749850B1 (en) 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
WO2001012236A2 (en) * 1999-08-18 2001-02-22 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
DK1223990T3 (da) 1999-10-15 2004-11-29 Inst Genetics Llc Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner
US7060676B2 (en) 1999-12-20 2006-06-13 Trustees Of Tufts College T. cruzi-derived neurotrophic agents and methods of use therefor
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
CA2411666A1 (en) * 2000-06-01 2001-12-06 Children's Medical Center Corporation Methods and compositions for producing a neurosalutary effect in a subject
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
EP1399023B1 (en) 2001-06-01 2008-04-30 Wyeth COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENETIC PROTEINS& x9;
CN1520312A (zh) * 2001-06-01 2004-08-11 �Ƹ��� T细胞诱导的组织修复和再生
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
US20060259014A1 (en) 2002-05-22 2006-11-16 Surgimark, Inc. Aspirator sleeve and suction handle
US20040229292A1 (en) * 2002-11-26 2004-11-18 Sebastiano Cavallaro Use of FGF-18 in the diagnosis and treatment of memory disorders
DE60331584D1 (de) 2002-11-26 2010-04-15 Biocon Ltd Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen
DE60334250D1 (de) 2003-05-08 2010-10-28 Life Technologies Corp Erzeugung und isolierung antigenspezifischer t-zellen
JP4971149B2 (ja) 2004-06-17 2012-07-11 スラソス セラピューティックス インコーポレーテッド Ｔｄｆ関連化合物およびその類似体
US8415298B2 (en) 2004-06-21 2013-04-09 The Board Of Trustees Of The Leland Stanford Junior University Of Stanford Administration of FGF2 for treamtent of anxiety
US20080108547A1 (en) * 2004-07-20 2008-05-08 Taylor Ii Larry Edmund Protease Inhibitor
WO2006011600A1 (ja) * 2004-07-29 2006-02-02 Anges Mg, Inc. 脳機能改善のための医薬および方法
US8697139B2 (en) 2004-09-21 2014-04-15 Frank M. Phillips Method of intervertebral disc treatment using articular chondrocyte cells
GB0425625D0 (en) * 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
PT2497780E (pt) 2005-09-20 2015-08-20 Thrasos Innovation Inc Compostos relacionados com tdf e seus análogos
EP1951908B1 (en) 2005-11-12 2013-08-07 The Board of Trustees of The Leland Stanford Junior University Fgf2-related methods for diagnosing and treating depression
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
US20100047299A1 (en) * 2007-01-25 2010-02-25 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh Use of gdf-5 for the improvement or maintenance of dermal appearance
US7678764B2 (en) 2007-06-29 2010-03-16 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations for use at elevated temperatures
WO2009020744A1 (en) 2007-08-07 2009-02-12 Johnson & Johnson Regenerative Therapeutics, Llc Protein formulations comprising gdf-5 in aqueous acidic solution
EP2276458A1 (en) * 2008-04-14 2011-01-26 Advanced Technologies and Regenerative Medicine, LLC Liquid buffered gdf-5 formulations
CN102369016A (zh) * 2009-02-12 2012-03-07 史赛克公司 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用
SG173634A1 (en) 2009-02-12 2011-09-29 Stryker Corp COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS
JP5749659B2 (ja) 2009-03-12 2015-07-15 ハーゼ インベストメンツ ウーゲー Ｂｍｐアンタゴニスト感受性が低下した骨形成タンパク質２（ｂｍｐ２）変異体
US20110002897A1 (en) 2009-06-11 2011-01-06 Burnham Institute For Medical Research Directed differentiation of stem cells
EP2352750B1 (en) 2009-09-17 2012-06-13 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
JP2013514811A (ja) 2009-12-22 2013-05-02 ストライカー コーポレイション 免疫原性が抑制されたｂｍｐ−７変異体
CN101822815A (zh) * 2010-04-29 2010-09-08 广东八加一医药有限公司 系列多肽小分子在制备防治缺血性脑血管疾病药物中的应用
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP2949338B1 (en) 2010-08-20 2017-10-25 Wyeth LLC Designer osteogenic proteins
EP2801377B1 (en) * 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel comprising cells for local release of growth factors to mediate motor recovery after stroke
KR101274930B1 (ko) * 2011-06-03 2013-06-17 전남대학교산학협력단 골 형성 또는 혈관신생 촉진용 펩타이드 ｂｆｐ 4 및 이의 용도
EP2734220A4 (en) * 2011-07-19 2015-01-21 Thrasos Innovation Inc ANTIFIBROTIC PEPTIDES AND THEIR USE IN METHODS OF TREATING FIBROSIS-CHARACTERIZED DISEASES AND SUFFERING
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
SG10201913751RA (en) 2013-05-06 2020-03-30 Scholar Rock Inc Compositions and methods for growth factor modulation
EP3881859B1 (en) * 2013-06-11 2024-03-06 President and Fellows of Harvard College Compositions for increasing neurogenesis and angiogenesis
EP4406585A3 (en) 2015-02-13 2024-10-23 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
CN109803977B (zh) 2016-08-17 2023-03-17 菲克特生物科学股份有限公司 核酸产品及其施用方法
US20200009226A1 (en) * 2018-07-03 2020-01-09 Cardiovascular Biotherapeutics, Inc. Compositions and Methods for Treating Stroke
US20230095167A1 (en) * 2020-02-20 2023-03-30 Universiteit Maastricht Detection method of circulating bmp10 (bone morphogenetic protein 10)
EP4154001A4 (en) * 2020-05-19 2024-06-05 Elevian, Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF STROKE
WO2024259004A1 (en) * 2023-06-13 2024-12-19 Bedford Research Foundation Systems and methods of cell transport at ambient temperature

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440860A (en) 1980-01-18 1984-04-03 The Children's Medical Center Corporation Stimulating cell growth
US4378347A (en) * 1980-06-30 1983-03-29 Franco Wayne P Composition for treating the heart for myocardial infarction
US4296100A (en) 1980-06-30 1981-10-20 Franco Wayne P Method of treating the heart for myocardial infarction
DE3110560A1 (de) 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
EP0105014B1 (en) 1982-09-24 1992-05-20 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Repair of tissue in animals
US4806523A (en) 1985-08-06 1989-02-21 Collagen Corporation Method of treating inflammation
US4971952A (en) 1986-03-06 1990-11-20 Collagen Corporation Method of treating inflammation with cartilage inducing factor
US4994559A (en) * 1985-12-17 1991-02-19 Synergen, Inc. Human basic fibroblast growth factor
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US4801575A (en) 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4861757A (en) 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
EP0269408A3 (en) 1986-11-26 1989-08-30 Genentech, Inc. Tgf-beta in the treatment of inflammatory disorders
US4797277A (en) 1987-09-22 1989-01-10 Pharmacia Ab Method for reperfusion therapy
US5108753A (en) 1988-04-08 1992-04-28 Creative Biomolecules Osteogenic devices
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
JPH0262829A (ja) 1988-05-18 1990-03-02 Nippon Kayaku Co Ltd 虚血に基づく傷害の予防及び治療剤
US4983581A (en) 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
FI910081A0 (fi) 1988-07-08 1991-01-07 Univ London Analys av cellmodifierande substanser.
AU4056089A (en) 1988-07-20 1990-02-19 Amgen, Inc. Method of treating inflammatory disorders by reducing phagocyte activation
US5057494A (en) 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
US5106626A (en) 1988-10-11 1992-04-21 International Genetic Engineering, Inc. Osteogenic factors
US5135915A (en) 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
US5011914A (en) 1989-01-05 1991-04-30 Collins Franklin D Purified ciliary neurotrophic factor
US5002965A (en) 1989-05-09 1991-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Use of ginkgolides to prevent reperfusion injury in organ transplantation
US5118791A (en) 1989-05-25 1992-06-02 Genentech, Inc. Biologically active polypeptides based on transforming growth factor-β
IL97365A0 (en) * 1991-02-27 1992-05-25 Yeda Res & Dev Pharmaceutical compositions comprising a lymphokine
US5158934A (en) 1989-09-01 1992-10-27 Genentech, Inc. Method of inducing bone growth using TGF-β
DK0448704T3 (da) 1989-10-17 1999-04-06 Stryker Corp Osteogene anordninger
US5108989A (en) 1990-04-04 1992-04-28 Genentech, Inc. Method of predisposing mammals to accelerated tissue repair
DE69131580T2 (de) 1990-06-15 2000-01-13 Carnegie Institution Of Washington, Washington GDF-1 und UOG1 Proteine
ATE253589T1 (de) 1990-09-26 2003-11-15 Inst Genetics Llc Bmp-5-derivate
WO1992007073A1 (en) 1990-10-18 1992-04-30 Creative Biomolecules, Inc. Osteogenic peptides
WO1992008480A1 (en) 1990-11-16 1992-05-29 Celtrix Pharmaceuticals, Inc. A β-TYPE TRANSFORMING GROWTH FACTOR
AU667188B2 (en) 1990-11-27 1996-03-14 American National Red Cross, The Tissue sealant and growth factor containing compositions that promote accelerated wound healing
CA2071912C (en) 1990-11-30 2002-10-15 Hanne Bentz Use of a bone morphogenetic protein in synergistic combination with tgf-beta for bone repair
DE69231946T2 (de) * 1991-03-11 2002-04-04 Curis, Inc. Protein-induzierende morphogenese
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
JPH07500315A (ja) 1991-05-10 1995-01-12 セルトリックス　ファーマシューティカルズ，インコーポレイテッド 骨成長因子の標的送達
CA2086327A1 (en) 1991-05-10 1992-11-11 Lawrence S. Mathews Cloning and recombinant production of receptor(s) of the activin/tgf- .beta. superfamily
ATE142460T1 (de) 1991-06-21 1996-09-15 Genetics Inst Osteogene proteine enthaltende arzneimittel
WO1993000432A1 (en) 1991-06-25 1993-01-07 Genetics Institute, Inc. Bmp-9 compositions
AU669127B2 (en) * 1991-08-30 1996-05-30 Stryker Corporation Morphogen-induced modulation of inflammatory response
ATE197611T1 (de) 1991-08-30 2000-12-15 Creative Biomolecules Inc Screeningverfahren von morphogenischen proteinen
DE69233559T2 (de) 1991-08-30 2006-08-31 Curis, Inc., Cambridge Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
ATE238417T1 (de) 1991-11-04 2003-05-15 Inst Genetics Llc Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
WO1993008828A1 (en) * 1991-11-08 1993-05-13 Syntex-Synergen Neuroscience Joint Venture Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration
JP4101284B2 (ja) 1991-11-22 2008-06-18 ジェネンテック・インコーポレーテッド 神経損傷を改善するｔｇｆ−ｂｅｔａ
DE19525416A1 (de) † 1995-07-12 1997-01-16 Bioph Biotech Entw Pharm Gmbh Verwendung von MP52 zur Behandlung und Prävention von Erkrankungen des Nervensystems
DK0653942T3 (da) * 1992-07-31 2003-10-20 Curis Inc Morphogen-induceret nerve-regenerering og -reparation
ES2061380B1 (es) * 1992-11-23 1995-07-01 Boehringer Ingelheim Espana Empleo del factor de crecimiento fibroblastico y sus derivados como neuroprotectores y neuromoduladores.
FI960809L (fi) 1993-08-26 1996-02-22 Genetics Inst Hermoregeneraatio käyttäen ihmisen luun morfogeneettisiä proteiineja
WO1995006656A1 (en) 1993-09-03 1995-03-09 The Regents Of The University Of California Neural tissue affecting factor and compositions
ATE355369T1 (de) 1993-10-14 2006-03-15 Harvard College Verfahren zur induzierung und zur erhaltung neuronalen zellen
AU6787594A (en) 1994-03-10 1995-09-25 Human Genome Sciences, Inc. Bone morphogenic protein-10
AU5244998A (en) * 1996-11-15 1998-06-03 Creative Biomolecules, Inc. Morphogen-induced regeneration of sense perceptory tissues

Also Published As

Publication number Publication date
CN1219133A (zh) 1999-06-09
ES2201287T3 (es) 2004-03-16
US20010039261A1 (en) 2001-11-08
DE69723429D1 (de) 2003-08-14
WO1997034626A1 (en) 1997-09-25
EP1364655A1 (en) 2003-11-26
KR20000064752A (ko) 2000-11-06
DE69723429T2 (de) 2004-04-22
JP2000507939A (ja) 2000-06-27
US6214796B1 (en) 2001-04-10
US6407060B1 (en) 2002-06-18
CA2249596C (en) 2011-11-08
DE69740089D1 (de) 2011-02-10
ES2201287T5 (es) 2007-10-16
ATE493141T1 (de) 2011-01-15
AU2552997A (en) 1997-10-10
CA2249596A1 (en) 1997-09-25
ATE244574T1 (de) 2003-07-15
US20030022830A1 (en) 2003-01-30
CA2249368A1 (en) 1997-09-25
WO1997034618A1 (en) 1997-09-25
EP0894004B1 (en) 2003-07-09
DE69723429T3 (de) 2007-09-20
AU734312B2 (en) 2001-06-07
EP1364655B1 (en) 2010-12-29
EP0904093A4 (en) 2004-11-17
AU725341B2 (en) 2000-10-12
EP0904093A1 (en) 1999-03-31
CN1181885C (zh) 2004-12-29
EP0894004A1 (en) 1999-02-03
AU2582397A (en) 1997-10-10
JP2000506894A (ja) 2000-06-06
EP0894004B2 (en) 2007-02-21

Similar Documents

Publication Publication Date Title
JP4847634B2 (ja) 中枢神経系の虚血または外傷の機能的回復を増大させる方法
JP4766722B2 (ja) 慢性腎不全の形態形成因子処置
Anand Neurotrophic factors and their receptors in human sensory neuropathies
US6723698B2 (en) Methods and compositions for the treatment of motor neuron injury and neuropathy
JP5346657B2 (ja) 組織形態形成および活性を評価するための方法
US6506729B1 (en) Methods and compositions for the treatment and prevention of Parkinson's disease
US20030170213A1 (en) Methods and compositions for enhancing cognitive function using morphogenic proteins
JP2009537555A (ja) 軟骨の欠損を処置するための可溶性形態形成タンパク質の使用
EP2352750B1 (en) Buffers for controlling the ph of bone morphogenetic proteins
Hagg et al. Prolonged local neurotrophin-3 infusion reduces ipsilateral collateral sprouting of spared corticospinal axons in adult rats
WO2000007611A1 (en) Treatment of central nervous system ischemia or trauma with epidermal growth factor-like polypeptides
AU767112B2 (en) Morphogen treatment for chronic renal failure
DE10317369A1 (de) proNGF als pharmazeutisch wirksames Mittel zur Behandlung demyelinisierender Erkrankungen
HK1064055A (en) Morphogenic proteins for enhancing cognitive function

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20060621

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20060807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060830

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20070508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20071016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071029

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20071220

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20080424

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20100204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110608

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20110607

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110809

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20111014

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20141021

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees